Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety
Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Almost 80% of panic disorder patients report difficulty sleeping. Sleep disturbances in turn
may exacerbate underlying anxiety/panic attacks. Moreover, individuals with insomnia (sleep
disturbance) are at higher risk of developing a new anxiety disorder. Therefore it is
expected that improving sleep quality with medications along with other medications to treat
anxiety component of panic disorder might be helpful. However, there is lack of
pharmacological studies examining the effects of improving sleep disturbances with
medications in panic disorder patients, which is a critical problem for providing optimal
care to these patients. The objective of this proposal is to determine the effects of
ramelteon (FDA approved for insomnia) on sleep disturbances in Panic disorder patients who
are on escitalopram for underlying anxiety.
Phase:
N/A
Details
Lead Sponsor:
Milton S. Hershey Medical Center Penn State University